A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Recruiting
Observational Study
Urothelial Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 202 (estimated)
- Sponsor
- Astellas Pharma Korea, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer.
People in this study will be adults in South Korea with locally advanced or metastatic urothelial cancer. Metastatic means the cancer has spread to other parts of the body. During their care, the person's doctor will have prescribed …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients who receive treatment with PADCEV Injection, according to the approved local label.
Exclusion Criteria:
* Patients with any contraindication for PADCEV Injection, according to the approved local label.
* Patients who receive or are going to receive any investigation…
Contacts